EP1569684A4 - Use of hmgb fragments as anti-inflammatory agents - Google Patents
Use of hmgb fragments as anti-inflammatory agentsInfo
- Publication number
- EP1569684A4 EP1569684A4 EP03789973A EP03789973A EP1569684A4 EP 1569684 A4 EP1569684 A4 EP 1569684A4 EP 03789973 A EP03789973 A EP 03789973A EP 03789973 A EP03789973 A EP 03789973A EP 1569684 A4 EP1569684 A4 EP 1569684A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- hmgb
- fragments
- inflammatory agents
- inflammatory
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940121363 anti-inflammatory agent Drugs 0.000 title 1
- 239000002260 anti-inflammatory agent Substances 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Marine Sciences & Fisheries (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42784602P | 2002-11-20 | 2002-11-20 | |
US42784102P | 2002-11-20 | 2002-11-20 | |
US427841P | 2002-11-20 | ||
US427846P | 2002-11-20 | ||
PCT/US2003/037507 WO2004046345A2 (en) | 2002-11-20 | 2003-11-20 | Use of hmgb fragments as anti-inflammatory agents |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1569684A2 EP1569684A2 (en) | 2005-09-07 |
EP1569684A4 true EP1569684A4 (en) | 2006-08-02 |
Family
ID=32329191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03789973A Withdrawn EP1569684A4 (en) | 2002-11-20 | 2003-11-20 | Use of hmgb fragments as anti-inflammatory agents |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1569684A4 (en) |
JP (1) | JP2006510619A (en) |
AU (1) | AU2003294488B2 (en) |
CA (1) | CA2506328A1 (en) |
NZ (1) | NZ540067A (en) |
WO (1) | WO2004046345A2 (en) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6303321B1 (en) | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
US7304034B2 (en) | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
US7696169B2 (en) | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
WO2005025604A2 (en) * | 2003-09-10 | 2005-03-24 | The General Hospital Corporation | Use of hmgb and hmgb fragments to decrease specific immune response |
EP1668035A2 (en) | 2003-09-11 | 2006-06-14 | Critical Therapeutics, Inc. | Monoclonal antibodies against hmgb1 |
AU2005259381A1 (en) * | 2004-07-02 | 2006-01-12 | Creabilis Therapeutics S.P.A. | Nucleic acids for the treatment of HMGB1-related pathologies |
US20080075728A1 (en) * | 2004-07-20 | 2008-03-27 | Walter Newman | Combination Therapies Of Hmgb And Complement Inhibitors Against Inflammation |
WO2006024547A2 (en) * | 2004-09-03 | 2006-03-09 | Creabilis Therapeutics S.P.A. | Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use |
AU2005333602B2 (en) * | 2004-10-22 | 2012-04-12 | Medimmune, Llc | High affinity antibodies against HMGB1 and methods of use thereof |
WO2006138429A2 (en) * | 2005-06-16 | 2006-12-28 | The Feinstein Institute For Medical Research | Antibodies against hmgb1 and fragments thereof |
US20100040608A1 (en) * | 2005-07-18 | 2010-02-18 | Marie Wahren-Herlenius | Use of HMGB1 antagonists for the treatment of inflammatory skin conditions |
WO2007031100A1 (en) * | 2005-09-14 | 2007-03-22 | Ostini, Marco | Active immunotherapy of life-threatening systemic inflammation |
AU2006312847A1 (en) * | 2005-11-09 | 2007-05-18 | Pharmexa A/S | Therapeutic vaccines targeting HMGB1 |
US8546547B2 (en) * | 2006-09-15 | 2013-10-01 | Creabilis Therapeutics S.P.A. | Polymer conjugates of Box-A of HMGB1 and Box-A variants of HMGB1 |
PL2066339T3 (en) | 2006-09-18 | 2015-02-27 | Univ Arkansas | Compositions and methods of enhancing immune responses |
US8470325B2 (en) | 2007-02-15 | 2013-06-25 | Kagoshima University | Method of treating amykloidosis comprising administering an anti-HMGB-1 antibody |
CA2722909A1 (en) | 2008-04-30 | 2009-11-05 | Genomix Co., Ltd. | Method for collecting functional cells in vivo with high efficiency |
AU2010312537A1 (en) | 2009-10-28 | 2012-05-17 | Genomix Co., Ltd. | Tissue-regeneration promoter using recruitment of bone marrow mesenchymal stem cells and/or pluripotent stem cells in blood |
DK2525817T3 (en) | 2010-01-21 | 2017-10-02 | Univ Arkansas | Vaccine vectors and methods for enhancing immune responses |
NZ702839A (en) | 2010-06-09 | 2016-04-29 | Univ Arkansas | Vaccine and methods to reduce campylobacter infection |
PT3358011T (en) | 2011-04-26 | 2020-04-23 | Univ Osaka | Peptide for inducing regeneration of tissue and use thereof |
RU2649069C2 (en) * | 2012-10-25 | 2018-04-02 | Дженомикс Ко., Лтд. | Novel method for treating spinal cord injury using hmgb1 fragment |
AU2013335684B2 (en) | 2012-10-25 | 2017-06-29 | Osaka University | Novel method for treating cardiac infarction using HMGB1 fragment |
SI2949675T1 (en) | 2013-01-28 | 2021-08-31 | Evec Inc. | Humanized anti-hmgb1 antibody or antigen-binding fragment thereof |
PT2956165T (en) | 2013-02-14 | 2019-11-29 | Texas A & M Univ Sys | Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection |
AU2014239557B2 (en) | 2013-03-15 | 2019-01-03 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to enteric pathogens |
JP7467027B2 (en) | 2016-05-03 | 2024-04-15 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー | Yeast vaccine vectors containing immunostimulatory and antigenic polypeptides and methods of using same |
CA3056088A1 (en) | 2017-03-15 | 2018-09-20 | Research Institute At Nationwide Children's Hospital | Composition and methods for disruption of bacterial biofilms without accompanying inflammation |
US11298403B2 (en) | 2017-12-01 | 2022-04-12 | StemRIM Inc. | Therapeutic agent for inflammatory bowel disease |
JP7386455B2 (en) * | 2018-02-08 | 2023-11-27 | 株式会社ステムリム | Treatment for psoriasis |
CN112823038A (en) * | 2018-10-05 | 2021-05-18 | 国家儿童医院研究所 | HMGB1 protein derivatives for removal of biofilm |
CN111743890A (en) * | 2019-03-26 | 2020-10-09 | 深圳先进技术研究院 | Application of daminomycin or derivatives thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1033401A2 (en) * | 1999-02-26 | 2000-09-06 | Genset | Expressed sequence tags and encoded human proteins |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6303321B1 (en) * | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
-
2003
- 2003-11-20 WO PCT/US2003/037507 patent/WO2004046345A2/en active IP Right Grant
- 2003-11-20 JP JP2004554020A patent/JP2006510619A/en active Pending
- 2003-11-20 AU AU2003294488A patent/AU2003294488B2/en not_active Ceased
- 2003-11-20 CA CA002506328A patent/CA2506328A1/en not_active Abandoned
- 2003-11-20 NZ NZ540067A patent/NZ540067A/en not_active IP Right Cessation
- 2003-11-20 EP EP03789973A patent/EP1569684A4/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1033401A2 (en) * | 1999-02-26 | 2000-09-06 | Genset | Expressed sequence tags and encoded human proteins |
Non-Patent Citations (4)
Title |
---|
DAILEY LISA ET AL: "Coevolution of HMG domains and homeodomains and the generation of transcriptional regulation by Sox/POU complexes", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 186, no. 3, March 2001 (2001-03-01), pages 315 - 328, XP002373261, ISSN: 0021-9541 * |
DATABASE Geneseq [online] 6 October 2000 (2000-10-06), "Human secreted protein, SEQ ID NO: 7904.", XP002373264, retrieved from EBI accession no. GSN:AAG03823 Database accession no. AAG03823 * |
ROGALLA P ET AL: "Mapping and molecular characterization of five HMG1-related DNA sequences", CYTOGENETICS AND CELL GENETICS, vol. 83, no. 1-2, 1998, pages 124 - 129, XP009063822, ISSN: 0301-0171 * |
YANG HUAN ET AL: "Reversing established sepsis with antagonists of endogenous high-mobility group box 1.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 101, no. 1, 6 January 2004 (2004-01-06), pages 296 - 301, XP002373262, ISSN: 0027-8424 * |
Also Published As
Publication number | Publication date |
---|---|
NZ540067A (en) | 2007-05-31 |
WO2004046345A2 (en) | 2004-06-03 |
WO2004046345A3 (en) | 2004-12-02 |
JP2006510619A (en) | 2006-03-30 |
CA2506328A1 (en) | 2004-06-03 |
AU2003294488A1 (en) | 2004-06-15 |
EP1569684A2 (en) | 2005-09-07 |
AU2003294488B2 (en) | 2007-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1569684A4 (en) | Use of hmgb fragments as anti-inflammatory agents | |
HUP0500042A3 (en) | Use of hmg fragments as anti-inflammatory agents | |
AU2003255482A1 (en) | Use of 4 amino-quinazolines as anti cancer agents | |
AU2003259735A8 (en) | Small-mer compositions and methods of use | |
AU2003285091A1 (en) | Interferon antagonists useful for the treatment of interferon related diseases | |
PL375784A1 (en) | Use of erythopoietin | |
AU2003299441A8 (en) | Nf-hev compositions and methods of use | |
AU2003295336A1 (en) | Use of etodoclac to treat hyperplasia | |
AU2003258662A1 (en) | Use of 4-amino-quinazolines as anti cancer agents | |
AU2003279841A1 (en) | Uses of human zven antagonists | |
AU2003278157A1 (en) | Novel phenylethanolamine derivatives and the use of the same as beta-3-agonists | |
GB2392618B (en) | Compositions for therapeutic use | |
IL165839A0 (en) | Compounds useful for the treatment of cancer compositions thereof and methods therewith | |
PL372655A1 (en) | Compositions of pentafluoropropane | |
GB0218798D0 (en) | Improvements to determination of ovulation | |
PL371427A1 (en) | New uses of substituted aminoalkanephosphonic acids | |
AU2003282510A8 (en) | Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents | |
EP1534293A4 (en) | Anti-inflammatory compositions and methods of use | |
AU2003270202A8 (en) | Pharmaceutical compositions useful for the treatment of cancers | |
AU2003298725A8 (en) | Preparation of metallotexaphyrins | |
AU2003240174A8 (en) | Compositions for the treatment of edematous-firbrosclerotic panniculopathy | |
AU2003252185A8 (en) | Topical composition for the treatment of scar tissue | |
EP1546326A4 (en) | Novel compositions and methods for the treatment of psoriasis | |
AU2003227519A1 (en) | The use of milnacipran for the treatment of tension-type headache | |
AU2003279282A8 (en) | Methods and compositions for the treament of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050616 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20060630 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: O'KEEFE, THERESA, L. Inventor name: NEWMAN, WALTER |
|
17Q | First examination report despatched |
Effective date: 20080818 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20081230 |